ADMA BIOLOGICS, INC.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “confident,” “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “position us,” “should,” “could,” “would,” “may,” “potential,” “opportunity” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the Company’s financial performance; total revenue, GAAP Net Income, Adjusted EBITDA, Adjusted Net Income, cash, working capital and margins guidance in future periods and related timing in connection therewith, as well as certain potential upside to such guidance; revenue and earnings growth and operational momentum, margin expansion and increased production output and efficiencies as a result of FDA approval of the yield enhancement process, and timing related thereto; our distribution network for ASCENIV and BIVIGAM and potential related growth; Company share repurchases and stockholder value; the Company’s insulation from global trade disruptions, tariffs and IRA-related pricing frameworks, as well as continuity, pricing stability, and competitive resilience; ASCENIV’s market penetration, expanded payer coverage and reimbursement, new patient growth and operational momentum; real-world health outcomes data relating to ASCENIV; our ability to optimize our operations and streamline our plasma network; and statements regarding SG-001 and its development, FDA review timing and revenue potential, as well as our overall product pipeline. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.